SeraCare Announces Expansion of AccuCell Line with Human Cord Blood Mononuclear Cells

SeraCare Life Sciences has expanded its line of AccuCell® mononuclear cells with the launch of off-the-shelf Human Cord Blood Monocuclear Cells (CBMNCs). The cells are ideal for use in stem cell research, drug discovery, vaccine manufacture, production of cell-based products and instrumentation, as well as cell production, translation, separation or expansion services.

In addition to the cryopreserved CBMNCs, SeraCare also provides custom CBMNC and PBMC isolations for both normal and disease-state material. Various fill sizes and cell counts from donors of diverse demographics are available. SeraCare also offers custom clinical research services to complement its CBMNC line, including whole blood fractionation, cell culture services, nucleic acid extraction, cellular analysis, immune monitoring assays and custom processing, analysis and storage.

“Through our global partnerships with hospitals, clinics and licensed centers, SeraCare has access to a consistent, ready supply of the human cord blood required to produce cryopreserved CBMNCs in the quantities our customers need, when they need it,” said Tina Patel, Associate Technical Product Manager, SeraCare Life Sciences. “Many of our customers need to obtain CBMNCs rapidly and often need to compare them to Peripheral Blood Mononuclear Cells during the course of their work. By providing both of these cell lines off-the-shelf for immediate shipment, SeraCare offers customers the time-savings and efficiencies of working with a single, trusted source for material that is vital to their research and manufacturing efforts.”

To ensure the highest purity and quality, SeraCare CBMNCs are processed at ISO-certified facilities following a rigorous, validated process, with donor material collected at facilities regulated by the U.S. Food and Drug Administration (FDA). The product is available in large lots to support long-term research initiatives and comparisons across multiple labs.